GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Short Percentage of Float

Oxurion NV (XBRU:OXUR) Short Percentage of Float


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Oxurion NV's Short Percentage of Float

For the Biotechnology subindustry, Oxurion NV's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxurion NV's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Short Percentage of Float falls into.


Oxurion NV (XBRU:OXUR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Short Percentage of Float
Comparable Companies
XBRU:ACCB XBRU:INCLU XBRU:ZEN XBRU:MCC XBRU:BAS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY
Traded in Other Exchanges
TG4:Germany
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Website
https://www.oxurion.com
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines